

Joseph M Blondeau

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8806554/joseph-m-blondeau-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54
papers

1,722
citations

18
h-index

41
g-index

68
ext. papers

2,051
ext. citations

3.9
avg, IF

5.06
L-index

#	Paper	IF	Citations
54	Mutant prevention concentrations of fluoroquinolones for clinical isolates of <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 433-8	5.9	266
53	Fluoroquinolones: mechanism of action, classification, and development of resistance. <i>Survey of Ophthalmology</i> , 2004 , 49 Suppl 2, S73-8	6.1	206
52	Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases. <i>Veterinary Medicine International</i> , 2011 , 2011, 263768	1.5	192
51	A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. <i>Journal of Antimicrobial Chemotherapy</i> , 1999 , 43 Suppl B, 1-11	5.1	136
50	Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). <i>Veterinary Dermatology</i> , 2014 , 25, 163-e43	1.8	135
49	International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats. <i>Veterinary Journal</i> , 2019 , 247, 8-25	2.5	105
48	New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. <i>Veterinary Dermatology</i> , 2009 , 20, 383-96	1.8	75
47	Mutant prevention concentration for ciprofloxacin and levofloxacin with <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , 2006 , 27, 120-4	14.3	54
46	Mutant prevention concentration of gemifloxacin for clinical isolates of <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 440-1	5.9	36
45	Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of <i>Mannheimia haemolytica</i> . <i>Veterinary Microbiology</i> , 2012 , 160, 85-90	3.3	32
44	Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 317-35	4	31
43	The evolution and role of macrolides in infectious diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 1131-51	4	31
42	Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option. <i>Drugs</i> , 2004 , 64, 611-28	12.1	30
41	Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of <i>Streptococcus pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 631-5	5.1	28
40	In vitro activity of tigecycline and comparators (2014-2016) among key WHO Priority pathogens and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 474-484	14.3	22
39	In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group. <i>Journal of Antimicrobial Chemotherapy</i> , 1999 , 43 Suppl A, 3-23	5.1	20
38	A review of clinical trials with fluoroquinolones with an emphasis on new agents. <i>Expert Opinion on Investigational Drugs</i> , 2000 , 9, 383-413	5.9	19

37	In vitro killing of <i>Escherichia coli</i> , <i>Staphylococcus pseudintermedius</i> and <i>Pseudomonas aeruginosa</i> by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat. <i>Veterinary Microbiology</i> , 2012 , 155, 284-90	3.3	18
36	Gemifloxacin: a new fluoroquinolone. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 1117-52	4	15
35	Characterization of carbapenem-resistant and XDR <i>Pseudomonas aeruginosa</i> in Canada: results of the CANWARD 2007-16 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, iv32-iv38	5.1	14
34	Gatifloxacin: a new fluoroquinolone. <i>Expert Opinion on Investigational Drugs</i> , 2000 , 9, 1877-95	5.9	14
33	Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens <i>Actinobacillus pleuropneumoniae</i> , <i>Pasteurella multocida</i> and <i>Streptococcus suis</i> . <i>PLoS ONE</i> , 2019 , 14, e0210154	3.7	14
32	Reporting elevated vancomycin minimum inhibitory concentration in methicillin-resistant <i>Staphylococcus aureus</i> : consensus by an International Working Group. <i>Future Microbiology</i> , 2019 , 14, 345-352	2.9	13
31	Epidemiology of bacterial corneal ulcers at tertiary centres in Vancouver, B.C. <i>Canadian Journal of Ophthalmology</i> , 2018 , 53, 330-336	1.4	13
30	Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. <i>Expert Opinion on Investigational Drugs</i> , 2001 , 10, 213-37	5.9	13
29	Tetrasodium EDTA Is Effective at Eradicating Biofilms Formed by Clinically Relevant Microorganisms from Patients' Central Venous Catheters. <i>MSphere</i> , 2018 , 3,	5	12
28	Besifloxacin in the management of bacterial infections of the ocular surface. <i>Canadian Journal of Ophthalmology</i> , 2015 , 50, 184-91	1.4	11
27	Quinupristin/dalfopristin. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 1341-64	4	11
26	Pradofloxacin: a novel veterinary fluoroquinolone for treatment of bacterial infections in cats. <i>Veterinary Journal</i> , 2014 , 201, 207-14	2.5	9
25	Role of gemifloxacin in the management of community-acquired lower respiratory tract infections. <i>International Journal of Antimicrobial Agents</i> , 2008 , 31, 299-306	14.3	9
24	Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of <i>Haemophilus influenzae</i> . <i>Eye and Contact Lens</i> , 2007 , 33, 161-162	3.4 ²	9
23	Advances in laboratory diagnostic technologies in clinical microbiology and what this means for clinical practice. <i>Clinical Practice (London, England)</i> , 2012 , 9, 347-352	3	8
22	Antibiotic dosing: do we dose to cure the individual or do we treat the greater societal needs?. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 511-516		7
21	Bacteremia with in a 4 month old pediatric oncology patient. <i>Journal of Chemotherapy</i> , 2020 , 32, 260-262.	3	6
20	Persistent infection with in an adult oncology patient with transmission from a family dog. <i>Journal of Chemotherapy</i> , 2020 , 32, 151-155	2.3	6

19	Application of two methods to determine killing of <i>Streptococcus pneumoniae</i> by various fluoroquinolones. <i>Journal of Chemotherapy</i> , 2006 , 18, 366-72	2.3	6
18	Bactericidal effects of various concentrations of enrofloxacin, florfenicol, tilmicosin phosphate, and tulathromycin on clinical isolates of <i>Mannheimia haemolytica</i> . <i>American Journal of Veterinary Research</i> , 2015 , 76, 860-8	1.1	5
17	Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6. <i>PLoS ONE</i> , 2020 , 15, e0237603	3.7	5
16	Comparative in vitro killing of canine strains of <i>Staphylococcus pseudintermedius</i> and <i>Escherichia coli</i> by cefovecin, cefazolin, doxycycline and pradofloxacin. <i>Veterinary Dermatology</i> , 2016 , 27, 267-e63	1.8	4
15	Susceptibility testing and reporting of new antibiotics with a focus on tedizolid: an international working group report. <i>Future Microbiology</i> , 2017 , 12, 1523-1532	2.9	4
14	Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting?. <i>Expert Review of Anti-Infective Therapy</i> , 2007 , 5, 53-9	5.5	4
13	Urinary tract infection in a human male patient with transmission from the family dog. <i>Journal of Chemotherapy</i> , 2021 , 1-4	2.3	3
12	Do we really understand what we want or need out of antimicrobial stewardship programs?. <i>Clinical Practice (London, England)</i> , 2013 , 10, 5-9	3	2
11	In vitro killing of canine strains of <i>Staphylococcus pseudintermedius</i> and <i>Escherichia coli</i> by cefazolin, cefovecin, doxycycline and pradofloxacin over a range of bacterial densities. <i>Veterinary Dermatology</i> , 2020 , 31, 187-e39	1.8	2
10	Recovery of borderline oxacillin-resistant (BORSP) from bone and soft tissue of a rheumatoid arthritis patient with severe osteoporosis: transmission from the family dog. <i>Journal of Chemotherapy</i> , 2021 , 33, 348-353	2.3	2
9	Clinical microbiology laboratories and COVID-19: an interview with Joseph Blondeau. <i>Future Microbiology</i> , 2021 , 16, 615-618	2.9	1
8	Diagnostic clinical microbiology. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2021 , 44, 250-269	1.4	1
7	A pilot study on the comparative minimum inhibitory and mutant prevention concentration values for moxifloxacin and pradofloxacin against canine and human isolates of <i>Staphylococcus pseudintermedius</i> and <i>S. schleiferi</i> . <i>Veterinary Dermatology</i> , 2019 , 30, 481-e142	1.8	0
6	The in vitro antibacterial activity of the anthelmintic drug oxyclozanide against common small animal bacterial pathogens. <i>Veterinary Dermatology</i> , 2019 , 30, 314-e87	1.8	
5	Methicillin-resistant replication in the presence of high (10^2 µg/ml) drug concentration of vancomycin as seen by electron microscopy. <i>Journal of Chemotherapy</i> , 2020 , 32, 179-187	2.3	
4	Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 357-373		
3	Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 357-373		
2	Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6. <i>Clinical Ophthalmology</i> , 2021 , 15, 4419-4430	2.5	

- 1 Antimicrobial Resistance **2021**, 163-174